Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
- Conditions
- Interventions
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2022-11-01
- Target Recruit Count
- 30
- Registration Number
- NCT02722941
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02676323
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2021-07-21
- Target Recruit Count
- 42
- Registration Number
- NCT02588339
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02568943
- Locations
- 🇸🇪
Novartis Investigative Site, Umea, Sweden
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT02506959
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT02471430
- Locations
- 🇺🇸
Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
CINC424A2X01B Rollover Protocol
- Conditions
- Interventions
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 356
- Registration Number
- NCT02386800
- Locations
- 🇹🇷
Novartis Investigative Site, Talas Kayseri, Turkey
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02204553
- Locations
- 🇺🇸
Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States
🇺🇸Sinai Hospital of Baltimore Sinai Hospital, Baltimore, Baltimore, Maryland, United States
🇺🇸Northern Utah Cancer Associates SC, Ogden, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.